Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 3Sarcoma 1Mycosis Fungoides 1Melanoma 1Inflammatory Breast Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Carcinoma, Ductal, Breast 1Carcinoma, Ductal 1Breast Carcinoma In Situ 1

Interventions

trametinib 1talimogene laherparepvec 1spartalizumab 1pembrolizumab 1nazartinib 1exemestane 1canakinumab 1Telomerase 1Tamoxifen 1Surgical Procedures, Operative 1Sentinel Lymph Node Biopsy 1Pemetrexed 1Paclitaxel 1Mastectomy, Subcutaneous 1Mastectomy, Segmental 1Mammaplasty 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ductal × talimogene laherparepvec × Breast × Clear all
NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
50 enrolled 12 charts
Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡